4basebio UK Societas Director/PDMR Shareholding
February 26 2021 - 1:00AM
UK Regulatory
TIDM4BB
26 February 2021
4basebio UK Societas
(the "Company")
Director's Dealing
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on
exploiting its intellectual property in the field of gene therapies and DNA
vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief
executive officer, acquired 3,000 ordinary shares at an average price of 345
pence per share on behalf of persons closely associated with him.
As a result of the acquisition of ordinary shares, Heikki Lanckriet's
beneficial holding, including shares held by persons closely associated with
him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the
Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.
For further enquiries, please contact:
4basebio UK Societas +44 (0)1223 967 943
Heikki Lanckriet
Nominated Adviser +44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker +44 (0)20 7220 0500
finnCap Ltd
Geoff Nash/Richard Chambers/Charlotte Sutcliffe
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Heikki Lanckriet
2 Reason for
notification
a. Position/Status Chief Executive Officer
b. Initial notification Initial
/
Amendment
3 Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a. Name 4basebio UK Societas
b. LEI 2138005D5SAG8FIR6G91
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of the Ordinary Shares
financial
instrument, type of
instrument ISIN: GB00BLD8ZL39
Identification Code
b. Nature of the Acquisition of ordinary shares
transaction
c. Price(s) and volume Volume(s) Price (p)
(s)
a. 1,000 345p
b. 1,000 345p
c. 1,000 345p
d. Aggregated
information -3,000
-345 pence per share
- Aggregated Volume
- Price
e. Date of the 25/2/2021
transaction
f. Place of the London Stock Exchange, AIM
transaction
END
(END) Dow Jones Newswires
February 26, 2021 02:00 ET (07:00 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Mar 2024 to Apr 2024
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2023 to Apr 2024